Standard BioTools
LAB
109 hedge funds and large institutions have $252M invested in Standard BioTools in 2015 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 36 increasing their positions, 35 reducing their positions, and 22 closing their positions.
67% more call options, than puts
Call options by funds: $12.8M | Put options by funds: $7.69M
14% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 22
2% more funds holding
Funds holding: 107 → 109 (+2)
3% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 35
66% less capital invested
Capital invested by funds: $750M → $252M (-$498M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
+$20.6M |
| 2 |
Capital World Investors
Los Angeles,
California
|
+$12.6M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
+$9.97M |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$8.87M |
| 5 |
Goldman Sachs
New York
|
+$7.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jennison Associates
New York
|
-$27.6M |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
-$16.7M |
| 3 |
JP Morgan Chase
New York
|
-$14.8M |
| 4 |
Luther King Capital Management (LKCM)
Fort Worth,
Texas
|
-$12.9M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
-$12.3M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CCS
126
Crosspoint Capital Strategies
Orinda,
California
| – | -$16K | -676 | Closed |
|
|
MFS
127
MSI Financial Services
Springfield,
Massachusetts
| – | -$7.68K | -488 | -97% |
|
128
SEI Investments
Oaks,
Pennsylvania
| – | +$16 | +1 | New |
|
|
LTFS
129
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | +$31 | +2 | New |
|
130
AssetMark Inc
Concord,
California
| – | +$63 | +4 | New |
|
LAB Hedge Fund Activity: Q3 2015 in Review
109 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Standard BioTools (LAB) for Q3 2015, worth a combined $252M — down 66% from $750M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new LAB positions and 22 closed out — a net gain of 3 holders — while 36 added to existing stakes and 35 trimmed.
The largest buyer was Scopia Capital Management, opening a new position worth an estimated $20.6M. The largest seller was Jennison Associates, cutting an estimated $27.6M.
- 109 institutional investors held Standard BioTools (LAB) as of Q3 2015, up from 107 in Q2 2015.
- Funds reported $252M of Standard BioTools stock for Q3 2015, down 66% quarter-over-quarter.
- 25 funds opened new Standard BioTools positions in Q3 2015 and 22 closed out, a net change of +3 holders.
- The largest Standard BioTools buyer in Q3 2015 was Scopia Capital Management, an estimated $20.6M added.
- The largest Standard BioTools seller in Q3 2015 was Jennison Associates, an estimated $27.6M sold.
Based on aggregated 13F filings for Q3 2015.